|
1
|
Gottesman MM and Pastan I: Biochemistry of
multidrug resistance mediated by the multidrug transporter. Annu
Rev Biochem. 62:385–427. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Goldstein LJ, Gottesman MM and Pastan I:
Expression of the MDR1 gene in human cancers. Cancer Treat
Res. 57:101–119. 1991.
|
|
3
|
Vasiliou V, Vasiliou K and Nebert DW:
Human ATP-binding cassette (ABC) transporter family. Hum Genomics.
3:281–290. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE
and Gottesman MM: P-glycoprotein: from genomics to mechanism.
Oncogene. 22:7468–7485. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Perez-Victoria JM, Di Pietro A, Barron D,
Ravelo AG, Castanys S and Gamarro F: Multidrug resistance phenotype
mediated by the P-glycoprotein-like transporter in Leishmania: a
search for reversal agents. Curr Drug Targets. 3:311–333. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Sauna ZE, Kim IW and Ambudkar SV: Genomics
and the mechanism of P-glycoprotein (ABCB1). J Bioenerg Biomembr.
39:481–487. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Dean M and Annilo T: Evolution of the
ATP-binding cassette (ABC) transporter superfamily in vertebrates.
Annu Rev Genomics Hum Genet. 6:123–142. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Janssen IJ, Krücken J, Demeler J, Basiaga
M, Kornaś S and von Samson-Himmelstjerna G: Genetic variants and
increased expression of Parascaris equorum P-glycoprotein-11
in populations with decreased ivermectin susceptibility. PLoS One.
8:e616352013.PubMed/NCBI
|
|
9
|
Shen DW, Lu YG, Chin KV, Pastan I and
Gottesman MM: Human hepatocellular carcinoma cell lines exhibit
multidrug resistance unrelated to MRD1 gene expression. J
Cell Sci. 98:317–322. 1991.PubMed/NCBI
|
|
10
|
Cordon-Cardo C, O’Brien JP, Boccia J,
Casals D, Bertino JR and Melamed MR: Expression of the multidrug
resistance gene product (P-glycoprotein) in human normal and
tumor tissues. J Histochem Cytochem. 38:1277–1287. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wu CP, Calcagno AM and Ambudkar SV:
Reversal of ABC drug transporter-mediated multidrug resistance in
cancer cells: evaluation of current strategies. Curr Mol Pharmacol.
1:93–105. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Robert J and Jarry C: Multidrug resistance
reversal agents. J Med Chem. 46:4805–4817. 2003. View Article : Google Scholar
|
|
13
|
Tan B, Piwnica-Worms D and Ratner L:
Multidrug resistance transporters and modulation. Curr Opin Oncol.
12:450–458. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Dantzig AH, de Alwis DP and Burgess M:
Considerations in the design and development of transport
inhibitors as adjuncts to drug therapy. Adv Drug Deliv Rev.
55:133–150. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Tsuruo T, Iida H, Tsukagoshi S and Sakurai
Y: Potentiation of vincristine and adriamycin effects in human
hemopoietic tumor cell lines by calcium antagonists and calmodulin
inhibitors. Cancer Res. 43:2267–2272. 1983.PubMed/NCBI
|
|
16
|
de Souza PS, da Cunha Vasconcelos F, Silva
LF and Maia RC: Cyclosporine A enables vincristine-induced
apoptosis during reversal of multidrug resistance phenotype in
chronic myeloid leukemia cells. Tumour Biol. 33:943–956.
2012.PubMed/NCBI
|
|
17
|
Shukla S, Wu CP and Ambudkar SV:
Development of inhibitors of ATP-binding cassette drug
transporters: present status and challenges. Expert Opin Drug Metab
Toxicol. 4:205–223. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Leonard GD, Polgar O and Bates SE: ABC
transporters and inhibitors: new targets, new agents. Curr Opin
Investig Drugs. 3:1652–1659. 2002.PubMed/NCBI
|
|
19
|
Boesch D, Gavériaux C, Jachez B,
Pourtier-Manzanedo A, Bollinger P and Loor F: In vivo circumvention
of P-glycoprotein-mediated multidrug resistance of tumor cells with
SDZ PSC 833. Cancer Res. 51:4226–4233. 1991.PubMed/NCBI
|
|
20
|
Germann UA, Shlyakhter D, Mason VS, et al:
Cellular and biochemical characterization of VX-710 as a
chemosensitizer: reversal of P-glycoprotein-mediated multidrug
resistance in vitro. Anticancer Drugs. 8:125–140. 1997. View Article : Google Scholar
|
|
21
|
Krishna R and Mayer LD: Multidrug
resistance (MDR) in cancer. Mechanisms, reversal using modulators
of MDR and the role of MDR modulators in influencing the
pharmacokinetics of anticancer drugs. Eur J Pharm Sci. 11:265–283.
2000.PubMed/NCBI
|
|
22
|
Müller H, Pajeva IK, Globisch C and Wiese
M: Functional assay and structure-activity relationships of new
third-generation P-glycoprotein inhibitors. Bioorg Med Chem.
16:2448–2462. 2008.PubMed/NCBI
|
|
23
|
Morschhauser F, Zinzani PL, Burgess M,
Sloots L, Bouafia F and Dumontet C: Phase I/II trial of a
P-glycoprotein inhibitor, Zosuquidar.3HCl trihydrochloride
(LY335979), given orally in combination with the CHOP regimen in
patients with non-Hodgkin’s lymphoma. Leuk Lymphoma. 48:708–715.
2007.PubMed/NCBI
|
|
24
|
van Zuylen L, Sparreboom A, van der Gaast
A, et al: Disposition of docetaxel in the presence of
P-glycoprotein inhibition by intravenous administration of R101933.
Eur J Cancer. 38:1090–1099. 2002.PubMed/NCBI
|
|
25
|
Guns ES, Bullock PL, Reimer ML, Dixon R,
Bally M and Mayer LD: Assessment of the involvement of CYP3A in the
vitro metabolism of a new modulator of MDR in cancer chemotherapy,
OC144–193, by human liver microsomes. Eur J Drug Metab
Pharmacokinet. 26:273–282. 2001.PubMed/NCBI
|
|
26
|
Zhou HY, Shen JK, Hou JS, Qiu YM and Luo
QZ: Experimental study on apoptosis induced by elemene in glioma
cells. Ai Zheng. 22:959–963. 2003.(In Chinese).
|
|
27
|
Zou L, Liu W and Yu L: beta-elemene
induces apoptosis of K562 leukemia cells. Zhonghua Zhong Liu Za
Zhi. 23:196–198. 2001.(In Chinese).
|
|
28
|
Li QQ, Wang G, Zhang M, Cuff CF, Huang L
and Reed E: β-Elemene, a novel plant-derived antineoplastic agent,
increases cisplatin chemosensitivity of lung tumor cells by
triggering apoptosis. Oncol Rep. 22:161–170. 2009.
|
|
29
|
Hu J, Jin W and Yang PM: Reversal of
resistance to adriamycin in human breast cancer cell line MCF-7/ADM
by β-elemene. Zhonghua Zhong Liu Za Zhi. 26:268–270. 2004.(In
Chinese).
|
|
30
|
Biedler JL and Riehm H: Cellular
resistance to actinomycin D in Chinese hamster cells in vitro:
cross-resistance, radioautographic, and cytogenetic studies. Cancer
Res. 30:1174–1184. 1970.PubMed/NCBI
|
|
31
|
Juliano RL and Ling V: A surface
glycoprotein modulating drug permeability in Chinese hamster ovary
cell mutants. Biochim Biophys Acta. 455:152–162. 1976. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Akiyama S, Fojo A, Hanover JA, Pastan I
and Gottesman MM: Isolation and genetic characterization of human
KB cell lines resistant to multiple drugs. Somat Cell Mol Genet.
11:117–126. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Carmichael J, DeGraff WG, Gazdar AF, Minna
JD and Mitchell JB: Evaluation of a tetrazolium-based semiautomated
colorimetric assay: assessment of radiosensitivity. Cancer Res.
47:943–946. 1987.PubMed/NCBI
|
|
34
|
Sodani K, Tiwari AK, Singh S, et al:
GW583340 and GW2974, human EGFR and HER-2 inhibitors, reverse
ABCG2- and ABCB1-mediated drug resistance. Biochem Pharmacol.
83:1613–1622. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Tiwari AK, Sodani K, Dai CL, et al:
Nilotinib potentiates anticancer drug sensitivity in murine ABCB1-,
ABCG2-, and ABCC10-multidrug resistance xenograft models. Cancer
Lett. 328:307–317. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Sun YL, Chen JJ, Kumar P, et al: Reversal
of MRP7 (ABCC10)-mediated multidrug resistance by tariquidar. PLoS
One. 8:e555762013. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Aller SG, Yu J, Ward A, et al: Structure
of P-glycoprotein reveals a molecular basis for poly-specific drug
binding. Science. 323:1718–1722. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Shi Z, Tiwari AK, Shukla S, et al:
Sildenafil reverses ABCB1- and ABCG2-mediated chemotherapeutic drug
resistance. Cancer Res. 71:3029–3041. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Dai CL, Tiwari AK, Wu CP, et al: Lapatinib
(Tykerb, GW572016) reverses multidrug resistance in cancer cells by
inhibiting the activity of ATP-binding cassette subfamily B member
1 and G member 2. Cancer Res. 68:7905–7914. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Ding PR, Tiwari AK, Ohnuma S, et al: The
phosphodiesterase-5 inhibitor vardenafil is a potent inhibitor of
ABCB1/P-glycoprotein transporter. PLoS One. 6:e193292011.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Huang XC, Sun YL, Salim AA, Chen ZS and
Capon RJ: Parguerenes: marine red alga bromoditerpenes as
inhibitors of P-glycoprotein (ABCB1) in multidrug resistant human
cancer cells. Biochem Pharmacol. 85:1257–1268. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Patel A, Tiwari AK, Chufan EE, et al:
PD173074, a selective FGFR inhibitor, reverses ABCB1-mediated drug
resistance in cancer cells. Cancer Chemother Pharmacol. 72:189–199.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Xu HB, Li L, Fu J, Mao XP and Xu LZ:
Reversion of multidrug resistance in a chemoresistant human breast
cancer cell line by β-elemene. Pharmacology. 89:303–312.
2012.PubMed/NCBI
|
